Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sharfstein Says Spiked Products Top FDA Supplement Enforcement Goals

This article was originally published in The Tan Sheet

Executive Summary

FDA Principal Deputy Commissioner Josh Sharfstein says that two to-do lists sit on his desk - one of urgent priorities that the agency must address immediately and one of important tasks that can wait

You may also be interested in...



Pfizer Guards Viagra Sales, Moves Against Tainted Supplements

A Pfizer study that finds 81% of sexual performance products claiming to be natural have undeclared pharmaceuticals could pressure FDA to increase enforcement and Congress to boost funding for the effort. The firm also launches online sales of Viagra to combat sales of counterfeit erectile dysfunction drugs.

Pfizer Guards Viagra Sales, Moves Against Tainted Supplements

A Pfizer study that finds 81% of sexual performance products claiming to be natural have undeclared pharmaceuticals could pressure FDA to increase enforcement and Congress to boost funding for the effort. The firm also launches online sales of Viagra to combat sales of counterfeit erectile dysfunction drugs.

Pfizer Guards Viagra Sales, Moves Against Tainted Supplements

A Pfizer study that finds 81% of sexual performance products claiming to be natural have undeclared pharmaceuticals could pressure FDA to increase enforcement and Congress to boost funding. The firm also launches online sales of Viagra to combat sales of counterfeit erectile dysfunction drugs.

Related Content

Topics

UsernamePublicRestriction

Register

PS103468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel